Ranibizumab in monotherapy and combined with photodynamic therapy for retinal angiomatous proliferation
Luis Arias,1–3 Francisco Gómez-Ulla,2–4 José M Ruiz-Moreno2,3,51Ophthalmology Department, Bellvitge University Hospital, C/Feixa Llarga, L’Hospitalet de Llobregat, Barcelona, 2Spanish Vitreoretinal Society (SERV), C/Xosé Chao Rego, Santi...
Guardado en:
Autores principales: | Arias L, Gómez-Ulla F, Ruiz-Moreno JM |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://doaj.org/article/542781159ffc4438b11c5d1aba783e07 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Predictive Factors And Long-Term Visual Outcomes After Anti-Vascular Endothelial Growth Factor Treatment Of Retinal Angiomatous Proliferation
por: Maruyama-Inoue M, et al.
Publicado: (2019) -
Efficacy and safety of ranibizumab monotherapy versus ranibizumab in combination with verteporfin photodynamic therapy in patients with polypoidal choroidal vasculopathy: 12-month outcomes in the Japanese cohort of EVEREST II study
por: Takahashi K, et al.
Publicado: (2018) -
Combination verteporfin photodynamic therapy ranibizumab-dexamethasone in choroidal neovascularization due to age-related macular degeneration: results of a phase II randomized trial
por: Gallemore RP, et al.
Publicado: (2017) -
Intravitreal aflibercept versus intravitreal ranibizumab for the treatment of diabetic macular edema
por: Fouda SM, et al.
Publicado: (2017) -
Evaluation of peripheral fundus autofluorescence in eyes with wet age-related macular degeneration
por: Suetsugu T, et al.
Publicado: (2016)